AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
Executive summary: AbbVie submitted a regulatory application to the European Medicines Agency for subcutaneous induction of risankizumab (SKYRIZI) in adults with moderate to severe active Crohn's disease, based on Phase 3 AFFIRM study data. Approval would provide a new, less invasive induction option for Crohn’s patients and expand the label for risankizumab, likely increasing AbbVie’s immunology sales.
Who is involved: AbbVie (sponsor), the European Medicines Agency (regulator), and investigators from the Phase 3 AFFIRM trial.
Likely next: The EMA will launch a centralized review, with a CHMP opinion expected within about 12 months, followed by a possible European Commission decision.
AbbVie has submitted a marketing authorization application to the European Medicines Agency for the subcutaneous induction formulation of risankizumab (SKYRIZI) in adults with moderate to severe active Crohn's disease. The filing relies on data from the Phase 3 AFFIRM study, which demonstrated efficacy and safety comparable to the existing intravenous induction regimen. If approved, the new indication would offer patients a less invasive dosing option and broaden the therapeutic use of risankizumab, potentially strengthening AbbVie’s position in the immunology market.
Timeline
- — AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease (PR Newswire)
Analysis — what this means
Sectors affected
- immunology
- gastroenterology
- biopharmaceuticals
Historical parallels
- AbbVie’s Humira replacement strategy reported 2026-08-24
- AbbVie presented new data at WCLC 2026 on 2026-08-21
Key entities
Sources
Open the full interactive case file on Beyond →